Govoni S, Lucchi L, Missale C, Memo M, Spano P F, Trabucchi M
Brain Res. 1986 Aug 27;381(1):138-42. doi: 10.1016/0006-8993(86)90701-8.
Haloperidol- and sulpiride-displaceable [3H]spiroperidol binding and the dopamine-inhibited adenylate cyclase were measured in rats chronically exposed to lead acetate. Haloperidol-displaceable [3H]spiroperidol binding was unmodified while sulpiride-displaceable binding was increased in striatum and decreased in nucleus accumbens. In addition, the decrease of sulpiride-displaceable binding in nucleus accumbens was paralleled by a reduced ability of bromocriptine to inhibit cAMP formation in presence of the D1 receptor antagonist SCH 23390. The results support the concept that in vivo lead treatment affects dopaminergic receptors and that the binding sites labelled by [3H]spiroperidol displaced by haloperidol may be different from those which recognize sulpiride.
在长期暴露于醋酸铅的大鼠中,测定了氟哌啶醇和舒必利可置换的[3H]螺哌啶结合以及多巴胺抑制的腺苷酸环化酶。氟哌啶醇可置换的[3H]螺哌啶结合未发生改变,而舒必利可置换的结合在纹状体中增加,在伏隔核中减少。此外,伏隔核中舒必利可置换结合的减少与在D1受体拮抗剂SCH 23390存在下溴隐亭抑制cAMP形成的能力降低相平行。这些结果支持这样的概念,即体内铅处理会影响多巴胺能受体,并且被氟哌啶醇置换的[3H]螺哌啶标记的结合位点可能与识别舒必利的位点不同。